about
Interaction of three beta-interferon domains with liposomes and monolayers as model membranes.Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritisThe use of chimeric vimentin citrullinated peptides for the diagnosis of rheumatoid arthritis.Updating the use of synthetic peptides as inhibitors of HIV-1 entry.Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug deliveryDefinition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.Design of synthetic peptidic constructs for the vaccine development against viral infections.Synthetic peptides for the immunodiagnosis of human diseases.Contribution of the Tyr-1 in Plantaricin149a to disrupt phospholipid model membranesDiagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis.HIV-1 inhibiting capacity of novel forms of presentation of GB virus C peptide domains is enhanced by coordination to gold compounds.Comparative study of the diagnostic and prognostic value of antibodies against chimeric citrullinated synthetic peptides and CCP3/CCP3.1 assays.Physicochemical characterization of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide: interaction with model membranes.Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.Structural Study of a New HIV-1 Entry Inhibitor and Interaction with the HIV-1 Fusion Peptide in Dodecylphosphocholine Micelles.Lipid raft-like liposomes used for targeted delivery of a chimeric entry-inhibitor peptide with anti-HIV-1 activity.Miscibility and Langmuir Studies of the Interaction of E2 (279-298) Peptide Sequence of Hepatitis G Virus/GB Virus-C with Dipalmitoylphosphatidyl Choline and Dimiristoylphosphatidyl Choline Phospholipids.A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1.Surface behavior of peptides from E1 GBV-C protein: Interaction with anionic model membranes and importance in HIV-1 FP inhibition.Modification of FP-HIV activity by peptide sequences of GB virus C: a biophysical approach.Antibodies against β-fibrin synthetic peptides: a study of their association with the immunogenetic background and disease course of rheumatoid arthritis patients.Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity.GB virus C (GBV-C) / hepatitis G virus (HGV): towards the design of synthetic peptides-based biosensors for immunodiagnosis of GBV-C/HGV infection.Study in mono and bilayers of the interaction of hepatitis G virus (GBV-C/HGV) synthetic antigen E2(99-118) with cell membrane phospholipids.Behaviour of a peptide sequence from the GB virus C/hepatitis G virus E2 protein in Langmuir monolayers: its interaction with phospholipid membrane models.Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.Design and application of GB virus C (GBV-C) peptide microarrays for diagnosis of GBV-C/HIV-1 co-infection.Effects of overlapping GB virus C/hepatitis G virus synthetic peptides on biomembrane models.Assessment of synthetic chimeric multiple antigenic peptides for diagnosis of GB virus C infection.Perturbations induced by synthetic peptides from hepatitis G virus structural proteins in lipid model membranes: a fluorescent approach.Characterization of a putative fusogenic sequence in the E2 hepatitis G virus protein.Antigenicity of chimeric and cyclic synthetic peptides based on nonstructural proteins of GBV-C/HGV.Interfacial properties of a synthetic peptide derived from hepatitis G virus E2 protein: interaction with lipid monolayers.Influence of the saturation chain and head group charge of phospholipids in the interaction of hepatitis G virus synthetic peptides.Diagnostic value of anti-GBV-C antibodies in HIV-infected patients.Effect of E1(64-81) hepatitis G peptide on the in vitro interaction of HIV-1 fusion peptide with membrane models.Liposome destabilization induced by synthetic lipopeptides corresponding to envelope and non-structural domains of GBV-C/HGV virus. Conformational requirements for leakage.Application of a chimeric synthetic peptide in the development of a serologic method for the diagnosis of hepatitis G virus infection.Lipophilic derivatization of synthetic peptides belonging to NS3 and E2 proteins of GB virus-C (hepatitis G virus) and its effect on the interaction with model lipid membranes.A Langmuir monolayer study of the interaction of E1(145-162) hepatitis G virus peptide with phospholipid membranes.
P50
Q33207049-7B5A8B63-FDEC-4654-8AA4-99CEFC6F9A42Q33805043-AC4AD269-506B-4A09-881C-6C2C7C9B716BQ34043771-62051F73-DB45-41C3-BEEA-B5585DDCCBCEQ34913398-073146DC-29D0-4CFF-91C5-DA4E77AF03C2Q35043797-E5B08836-E2DC-4497-82DE-AB71B2233D4FQ35932316-E0E96EB6-F7D8-48E5-8536-EB040D0E5A50Q35974145-B3525D6C-1106-4803-8DAB-D74DFAD541E2Q36754516-46B124DB-DC2A-486A-BDA2-98D3F02A6E05Q37007318-DE081E5B-E0C3-4C82-83B5-28E8C08F4BD9Q37453967-14DDA705-E469-41EA-B469-D754ACFA5438Q38148239-F4C3052A-F767-4F72-8A3E-BD8FEA337BFAQ38603829-F9361A33-33AA-4395-92FF-F582790BDCFDQ39573628-8C135F6C-458D-4642-82D4-240B83397012Q39666265-22E9CEEE-02F4-410A-8FAF-C76E922B01DAQ40134876-FC0D73A8-5710-43EC-A467-F06EF45A8B11Q40561802-DC1E75F5-E5A7-4F37-AA65-DE24C6BA3F7DQ41597709-0B942879-60D1-4A78-A9EA-ED5FF381DD11Q41740298-3218C42F-C59B-405C-8AE9-093EFD2ADE66Q42178285-D7535F7A-7D47-4695-BFF6-C6121FDCADB9Q42236839-9EFD2797-A8CD-471B-BD40-5ED45809798FQ42689017-A0E294EA-1E3E-4C3E-BA29-260ED812FABEQ42747358-48A7BC13-C215-45D6-8C9A-89C6BB96988BQ42980581-5F153EC9-7EE9-4295-BA67-DDC98088C8FBQ42984644-AF33CDBE-C1AD-4CA9-BD7D-7DCDCBE40F47Q42985497-B1D3CCCD-AA40-4C8B-A4EB-DD36542A57E7Q42987190-09A234F3-DBED-4CB6-A654-2A066D536A7AQ42987192-37B58A5F-F592-4B04-AC13-D5FCDDC7CFD6Q42989198-56653F9D-5200-4D86-8E83-F6F5FABF8A1BQ42990920-FC93E54F-517F-4EC3-9EBD-A9BD68FCF9C9Q42994877-AE69797D-9BC1-4A55-9657-FF571FD305A5Q42995201-34ACC30E-0103-4A54-8DE4-2E100E28EEA2Q42995394-4A5F1D7F-FBBB-4AB2-9DA7-806BF09464C1Q42997358-1B7F9797-EB98-40C4-A4C1-DECBC7BBC119Q43001377-5B6329B7-DBB9-41D5-AA76-E9593D0243E2Q43036978-1B18D11B-84CB-4858-ABF0-FF97C3A0F680Q43037716-3C2BA0A5-1578-4055-B2B4-115717B8BFE6Q43041936-C3FB2E7E-F156-4B99-9C3D-9B06EE89496BQ43042440-78D81872-E2E7-4952-8E51-B02881302BAAQ43048545-E6F6CAF1-F5CE-4541-80F3-91B6A4D27CA1Q43226125-2F4FCC50-CD33-498E-9ABC-6913FE57E103
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Isabel Haro
@ast
Isabel Haro
@en
Isabel Haro
@es
Isabel Haro
@sl
type
label
Isabel Haro
@ast
Isabel Haro
@en
Isabel Haro
@es
Isabel Haro
@sl
prefLabel
Isabel Haro
@ast
Isabel Haro
@en
Isabel Haro
@es
Isabel Haro
@sl
P108
P1053
N-8719-2014
P106
P1153
7006064539
P21
P31
P3829
P496
0000-0001-8677-2340